New Drug ACE-011 Acceleron Pharma

Acceleron Pharma eports that it will expand its workforce and build new offices and facilities this year. The company signed a lease in Cambridge, MA, further expanding its research laboratory and office space by 19,700 sq. ft. In conjunction with this, Acceleron will increase its workforce by more than 50% to support growth in R&D and manufacturing.

Acceleron’s lead program, ACE-011, is currently in Phase II studies in multiple myeloma patients with osteolytic bone disease. ACE-011 has been shown to increase bone mineral density and red blood cells and is being jointly developed by Acceleron and Celgene.